Compare abrdn Physical Palladium Shares ETF (PALL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs Viatris Inc — how do they compare? abrdn Physical Palladium Shares ETF trades at $23.33, while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc pays a 2.73% dividend while abrdn Physical Palladium Shares ETF pays none, and Viatris Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| PALL | VTRS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $17.59 |
52-Week Low | $19.96 | $8.74 |
Market Cap | — | $20.50B |
Enterprise Value | — | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL trades at $22.80, up 0.44% on the day, with a bearish technical signal from moving averages. The stock recently underwent a 1:5 forward split effective May 18, 2026. Recent news highlights palladium's underperformance in the precious metals rally, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on a recovery in palladium prices, with sentiment mixed. Opportunities exist if industrial demand strengthens and supply constraints materialize, but risks include continued commodity price volatility and broader economic pressures that could dampen demand.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
